Double-blind studies are not always optimum for evaluation of a novel therapy: the case of new anticoagulants.
Academic Medical Centre, Amsterdam, The Netherlands. h.r.buller@amc.uva.nl
H R
HR
Büller
J L
JL
Halperin
H
H
Bounameaux
M
M
Prins
D000925:Anticoagulants / Q000592:standards / Q000627:therapeutic use*; D015982:Bias; D019090:Case Management; D017326:Clinical Trials, Phase III as Topic / Q000379:methods / Q000592:standards; D003362:Cost-Benefit Analysis; D004311:Double-Blind Method; D005343:Fibrinolytic Agents / Q000592:standards / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D018579:Patient Selection; D011364:Professional Practice; D011517:Prothrombin Time / Q000295:instrumentation; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic / Q000379:methods* / Q000592:standards; D019851:Thrombophilia / Q000188:drug therapy; D016896:Treatment Outcome; D014812:Vitamin K / Q000037:antagonists & inhibitors
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D014812:Vitamin K; D006493:Heparin